Research output per year
Research output per year
Personal profile
Overview
Recently, I have joined the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). BADBIR is a drug safety register seeking to assess the long-term safety of drug treatments for psoriasis in a realworld population of psoriasis patients. My main role includes statistical analyses and writing peer-reviewed publications. My research interests are survival analysis, mixed multilevel and structural modelling.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Doctor of Philosophy
Keywords
- Epidemiology
- Drug safety
Fingerprint
Dive into the research topics where Oras Alabas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BADBIR Study Group, Alabas, O. A., Mason, K. J., Yiu, Z. Z. N., Smith, C. H., Warren, R. B. & Griffiths, C. E. M., 10 Jan 2025, (E-pub ahead of print) In: The British journal of dermatology. ljaf017.Research output: Contribution to journal › Article › peer-review
Open Access -
A sprinkle of methotrexate to go with biologics: a safe recipe?
Alabas, O. A. & Yiu, Z. Z. N., 1 Mar 2024, In: The British journal of dermatology. 190, 3, p. 302-303 2 p.Research output: Contribution to journal › Editorial › peer-review
-
Characteristics of "Super-Responders" and "Super-Non-Responders" to First Biologic Monotherapy for Psoriasis: A Nested Case-control Study
BADBIR Study Group, Mason, K. J., Alabas, O. A., Dand, N., Warren, R. B., Reynolds, N. J., Barker, J. N. W. N., Yiu, Z. Z. N., Smith, C. H. & Griffiths, C. E. M., 1 Mar 2024, In: The British journal of dermatology. 190, 3, p. 441-444 4 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Riley, R. D., Warren, R. B. & Williams, H. C., 15 Mar 2024, In: The British journal of dermatology. 190, 4, p. 559-564 6 p., ljad430.Research output: Contribution to journal › Article › peer-review
Open Access -
Risk of incident cancer, excluding keratinocyte carcinoma, in patients with psoriasis treated with biologic therapy: a prospective cohort study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), on behalf of the BADBIR Study Group
Esse, S., Alabas, O., Mason, K., Ryan, S., Reynolds, N. J., Smith, C., Green, A. & Warren, R. B., 1 Jul 2024, In: British Journal of Dermatology. 191, p. i48 1 p., P072.Research output: Contribution to journal › Meeting Abstract › peer-review